These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26267023)

  • 1. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
    Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
    Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
    Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
    Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
    Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
    Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
    J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
    Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
    Urology; 2016 Oct; 96():171-176. PubMed ID: 27318265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
    Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
    Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.